A randomized trial of 24-week versus 48-week courses of pegintereron plus ribavirin for genotype 1 hepatitis C and IL28B CC polymorphism.

Trial Profile

A randomized trial of 24-week versus 48-week courses of pegintereron plus ribavirin for genotype 1 hepatitis C and IL28B CC polymorphism.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2013 Planned End Date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 02 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top